TOROCEF-1

Indications

• Community-acquired pneumonia
• Meningitis
• Skin and soft tissue infections
• Bone and joint infections
• Intra-abdominal infections
• Urinary tract infections

Mechanism of action

Ceftriaxone works by inhibiting mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane, which are crucial for cell-wall synthesis and cell division. This binding leads to loss of enzyme activity, resulting in the production of defective cell walls and ultimately causing bacterial cell death.

Pharmacodynamics

Ceftriaxone exhibits bactericidal activity, primarily through the inhibition of cell wall synthesis mediated by its binding to penicillin-binding proteins (PBPs). It is effective against a variety of bacteria, including gram-positive and gram-negative organisms, and shows stability against hydrolysis by several beta-lactamases. However, resistance can develop through beta-lactamase production, alterations in PBPs, or reduced permeability of the bacterial cell wall. It is important to note that ceftriaxone should not be mixed or administered in the same IV line with calcium-containing products due to the risk of precipitation.

Pharmacokinetics

Ceftriaxone has a high volume of distribution and is widely distributed throughout the body, including in the central nervous system. It is primarily eliminated via the urine, with approximately 50-60% of the dose excreted unchanged. The drug has a long half-life, which supports once-daily dosing. Ceftriaxone's pharmacokinetics can be influenced by factors such as age, renal function, and severity of infection.

Contra-indications

• Hypersensitivity to ceftriaxone or other cephalosporins
• Newborns who require calcium treatment due to the risk of precipitation

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Anaphylaxis
• Biliary sludge or gallbladder pseudolithiasis
• Elevated liver enzymes
• Thrombocytopenia

Interactions

• Calcium-containing solutions or medications (risk of precipitation)
• Probenecid (may increase ceftriaxone levels)
• Aminoglycosides (may increase nephrotoxicity)

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of an allergic reaction
• Evaluate liver function periodically during prolonged therapy
• Be aware of potential for superinfection with prolonged use

Pregnancy

Ceftriaxone is classified as category B. Animal studies have not demonstrated risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Ceftriaxone is excreted in breast milk in small amounts. Caution is advised when administering to nursing mothers.

Storage

Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Protect from light and moisture.

Formulations

• Intravenous injection
• Intramuscular injection
• Powder for solution for injection

Indications

• Surgical procedures
• Injection of medications
• Preparation of sterile pharmaceutical products
• Management of open wounds
• Use in controlled environments such as hospitals and laboratories

Dosage

Children: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Adults: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Mechanism of action

Sterility itself does not have a mechanism of action as it is a state of cleanliness and does not interact with biological systems. However, the methods used to achieve sterility, such as heat or chemical agents, act by denaturing proteins, disrupting cellular structures, or damaging nucleic acids in microorganisms, leading to their inactivation or destruction.

Pharmacodynamics

The pharmacodynamics of sterile techniques primarily involves the prevention of microbial infection and contamination when administering medications. By ensuring that products are sterile, the risk of adverse effects related to infections is minimized. The effectiveness of sterilization methods can be influenced by factors such as temperature, duration of exposure, and the type of microorganisms present.

Pharmacokinetics

As sterility does not pertain to a specific drug, pharmacokinetics is not applicable. However, the pharmacokinetics of a drug will depend on its formulation, route of administration, and the presence of preservatives or stabilizers that may be used alongside sterile preparations.

Pregnancy

Sterile preparations are generally considered safe during pregnancy as they are used to provide hydration, nutrition, or medications in a controlled manner, but specific formulations should be assessed individually.

Breast-feeding

Sterile solutions used for hydration or nutritional support are typically safe during breastfeeding, but any specific additives or medications within the solutions should be evaluated for safety.

Storage

Sterile solutions should be stored in a cool, dry place, protected from light, and should be used before the expiration date. Once opened, they may have specific storage requirements based on the formulation.

Formulations

• Sterile saline solution
• Sterile water for injection
• Sterile dextrose solution
• Sterile electrolyte solutions

Mechanism of action

Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. Binding of ceftriaxone to these enzymes causes the enzyme to lose activity; therefore, the bacteria produce defective cell walls, causing cell death.

Pharmacodynamics

Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has <i>in vitro</i> activity against gram-positive aerobic, gram-negative aerobic, and anaerobic bacteria. The bactericidal activity of ceftriaxone results from the inhibition of cell wall synthesis and is mediated through ceftriaxone binding to penicillin-binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended-spectrum beta-lactamases. However, resistance to ceftriaxone usually occurs through beta-lactamase hydrolysis, altered PBPs, or reduced bacterial cell permeability. Ceftriaxone should not be mixed with or giving in the same IV line as diluents/products containing calcium as they may cause ceftriaxone to precipitate. Ceftriaxone use may also cause biliary sludge or gallbladder pseudolithiasis.